Orforglipron (Foundayo) Weight Loss Pills: A Guide

The medical landscape is constantly evolving, with new treatments being developed all the time. Foundayo, containing the active ingredient orforglipron, is one such example. Manufactured by Eli Lilly, the company behind Mounjaro injections, this new medication is an oral GLP-1 tablet that is taken daily.

Foundayo is the second GLP-1 pill to be approved by the Medicines and Healthcare products Regulatory Agency (MHRA) for weight management, gaining authorisation in August 2026. This development meant the UK was the first country in Europe to give orforglipron the green light. The first oral GLP-1 medication to be approved in the UK for this purpose was the Wegovy pill, a tablet-based alternative to Wegovy injections.

Having a clear understanding of new medications is crucial to making an informed decision about whether it may be suitable for your circumstances. This article outlines everything you need to know about orforglipron weight loss pills, including how they work, what side effects they cause, and, most importantly, how effective they are for weight loss. Let’s get started.  

How Does Orforglipron Work?

Orforglipron is a daily, oral GLP-1 medication that works by mimicking the effects of a hormone called GLP-1 (glucagon-like peptide-1). The intestines naturally release GLP-1 when you eat, and it has a variety of effects in the body:

• Acts on the brain to increase satiety
• Slows the rate of digestion
• Stimulates the release of insulin from the pancreas

By increasing satiety and slowing digestion, GLP-1 can reduce appetite and food intake. It also regulates blood sugar levels by promoting the release of insulin, a hormone that facilitates the movement of glucose from the bloodstream into cells. Therefore, medications that imitate the effects of GLP-1 have potential benefits for both weight management and blood glucose control.

GLP-1 medications, such as orforglipron, activate the same processes as natural GLP-1, but they do so more effectively. GLP-1 produced by the body breaks down within 1-5 minutes of its release, due to the action of an enzyme called DPP-4. Synthetic GLP-1, however, is designed to resist degradation by DPP-4 and remains active in the body for much longer. This enhances GLP-1’s effects on satiety and blood sugar regulation, often translating to better weight loss outcomes for users.

Is Orforglipron Effective for Weight Loss?

Clinical trials have shown that orforglipron can be highly effective for weight loss. Like other GLP-1s, orforglipron reduces appetite and ‘food noise’ by slowing gastric emptying (i.e., the rate at which food moves through the stomach). This makes users feel fuller more quickly than usual, frequently leading to a significant reduction in food and calorie intake.

The effects of orforglipron are dose-dependent, with the greatest weight reductions produced by higher doses. Clinical trials have reported mean body weight reductions of 12-15% in non-diabetic patients and 10-12% in diabetic patients after 72 weeks of treatment with the highest dose. Participants also saw significant improvements in other key cardiovascular and metabolic health markers, including:

• Reduced waist circumference
• Improved body composition
• Improved systolic and diastolic blood pressure
• Reduced non-HDL cholesterol levels
• Better blood glucose control

Further research suggests that orforglipron is superior to oral semaglutide for both blood sugar control and weight loss. However, it does not promote the same weight loss to the same degree as some injectable medications, like tirzepatide, which can produce body weight reductions of over 20%.

Benefits of Orforglipron Tablets vs Injections

Orforglipron tablets have several potential benefits over weight loss injections. Their oral bioavailability makes them easier to use than injectables and bypasses the risk of injection site reactions. Orforglipron pills may also produce a slower rate of weight loss than injections, or help people to maintain their lower weight after discontinuing Mounjaro or Wegovy.

Ease of Use

The key benefit of orforglipron tablets over weight loss injections is their comparative ease of use, rather than their weight loss efficacy. Although orforglipron can promote significant weight loss, its results may not meet those produced by some injectable medications (like tirzepatide). However, as orforglipron is an oral medication, it may be a better choice for people who don’t want to self-inject.

Avoid Skin Irritation

Weight loss injections are easy to administer at home, but they can produce skin irritation. Injection site reactions (including rash, redness, and itching) are a common side effect of GLP-1 injections. By choosing orforglipron tablets, GLP-1 users can bypass these risks entirely. Weight loss pills may also be an attractive alternative for people with needle anxiety, or for those with limited dexterity and mobility.

Slower Rate of Weight Loss

Injectable weight loss medications, like tirzepatide, can produce rapid weight loss. This may benefit those with weight-related health conditions, but can also increase the risk of health concerns like poor nutrition, reduced bone and muscle mass, and telogen effluvium (hair loss). Therefore, orforglipron pills may be a preferable choice for people hoping to lose weight more slowly.

Weight Maintenance

Another potential issue facing people who use weight loss injections is weight regain. Research has found that people often put on weight rapidly after stopping treatment and regain, on average, 60% of their lost weight within a year. Orforglipron may provide a solution to this concern, as experts believe the pills could help people ‌maintain their lower weight after coming off injections.

Orforglipron Pill Side Effects

As with other GLP-1 medications, the most common side effects of orforglipron affect the gastrointestinal system and include nausea, vomiting, and diarrhoea. These symptoms are dose-dependent and, usually, mild to moderate in severity. They may flare up at the start of treatment or get worse around dose increases, but often get better as your body adjusts to the drug.

Other potential side effects of orforglipron include:

• Constipation
• Indigestion
• Abdominal pain
• Headache
• Bloating
• Fatigue
• Belching
• Gas
• Heartburn
• Hair loss

Orforglipron is also associated with an increased risk of hypoglycemia, or very low blood sugar. This side effect is most commonly seen in people using weight loss pills alongside insulin or other anti-diabetic medications. Always tell your prescribing clinician about any other medications you are taking before starting a new treatment.

In rare cases, orforglipron can cause more serious side effects. For example, dehydration brought about by vomiting and diarrhoea can lead to kidney damage. Other rare but serious health implications of orforglipron use include pancreatitis and acute gallbladder disease. If you experience severe or persistent side effects, contact a healthcare professional for medical assessment and advice.

Who Will Be Eligible for Orforglipron Tablets?

In the UK, orforglipron pills will be prescribed to those with a BMI of 30 or above, or a BMI between 27 and 30 with at least one weight-related health concern. Those with type 2 diabetes may also be eligible, as orforglipron can help to improve blood sugar control.

Doctors recommend that people use weight loss medications as part of a comprehensive weight management plan that includes a reduced-calorie diet and increased physical activity. The pills will be available in a variety of doses; treatment begins at 0.8 mg and escalates through 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and 17.2 mg. Users should stay on each dose for at least one month before titrating up.

When Will Orforglipron Be Available in the UK?

Orforglipron was approved for prescription in the UK on 10th August 2026. Though it won’t be immediately available via NHS prescription, the medication could arrive in private pharmacies within weeks. A Lilly spokesperson confirmed to Reuters that Foundayo (orforglipron’s brand name) will launch later that same month. 

Where to Buy Orforglipron in the UK

Orforglipron (Foundayo) will become available via private prescription in the UK. This means you’ll be able to obtain it from licensed prescribers such as weight management clinics and online pharmacies. It won’t be available over-the-counter. 

How Much Will Orforglipron Cost in the UK?

The exact cost of orforglipron weight loss tablets won’t be known until they become available in the UK. Pricing usually depends on a number of variables, including distribution costs and other manufacturing factors. The dose of the treatment also needs to be taken into account, with higher strengths being more expensive. 

Frequently Asked Questions

There are a variety of weight loss medications now available on the UK market, with new options always in development. Here, we’ll cover some of the most commonly asked questions about orforglipron: is this medication a GLP-1, will it be available on the NHS, and can you switch over to orforglipron from other weight loss drugs?

Is Orforglipron a GLP-1?

Orforglipron is a small-molecule GLP-1 drug. It is in the same class of medications as tirzepatide (Mounjaro) and semaglutide (Wegovy injections and Wegovy pills), but its structure and mechanism of action are different. Tirzepatide and semaglutide are peptide-based molecules. These are chains of amino acids that mimic the structure of natural GLP-1 and produce the same effects in the body. Tirzepatide also acts on GIP receptors, making it a dual agonist.  

Small-molecule GLP-1s, like orforglipron, are single chemical compounds. Orforglipron binds to and activates the GLP-1 receptor, triggering a chain of events that produces the physiological reactions associated with GLP-1 (i.e., slower gastric emptying and blood sugar control).

Will Orforglipron Be Available on the NHS?

Orforglipron will not be available on the NHS to start with, and there is no indication of whether or when this will change. The National Institute for Health and Care Excellence (NICE) will first need to evaluate whether the treatment is clinically and cost-effective before it can be approved for NHS use.  

Even if Foundayo is approved for the NHS, eligibility requirements could be more stringent than if you used a private service, and there is likely to be a long waiting list. This is what happened when Mounjaro became available on the NHS. 

Will I Be Able to Switch to Orforglipron from Other Medications?

Yes, you will be able to switch to orforglipron from other weight loss treatments such as Mounjaro, Wegovy injections, or Wegovy pills. Exact processes won’t be clear until Foundayo becomes available. 

Weight Loss Support You Can Rely Upon

If you’re looking for specialist and continued support during your weight loss journey, Prescription Doctor is here to help. Since 2013, we’ve established a strong reputation for quality and reliability, alongside a tailored consultation service that is designed to match your unique circumstances.

With us, there’s no need to make an appointment. All it takes is a straightforward online consultation that you can complete at any time from your own home. Answer a few medical questions, and our experienced clinicians will be able to determine whether your chosen medication is suitable for you, or if an alternative may be a better choice. Once approved, your order will be dispatched by our General Pharmaceutical Council-registered pharmacy in plain packaging for complete discretion. Anything approved before 3pm Monday to Friday is also eligible for next-day delivery. It’s that straightforward.

Our clinicians will regularly check in with you to ensure that everything is working as planned and you are having the desired results. You can also contact them via your online account any time you need additional support or advice about your treatment. We are here to help you succeed. 

Authored By

Kate Latham

Medical Content Writer

Kate has been a scientific content writer since 2017. With a BSc in Biology and a background in cancer research, she is adept at identifying the latest findings in medical research and utilising these

Published on: 18/08/2026

Reviewed By

Mohamed Imran Lakhi

MPharm - Lead Pharmacist

Imran Lakhi is the superintendent pharmacist and founder at Prescription Doctor. He has been at the core of our team.

Reviewed on: 18/08/2026